Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gadolinium Imaging Agents To Get Safety Review At FDA Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

Sponsors are conducting mandatory clinical trials on the risk for patients with moderate to severe renal insufficiency.
Advertisement

Related Content

FDA Safety Panel: All MRI Gadolinium Contrast Agents Are Not Created Equal
FDA Safety Panel: All MRI Gadolinium Contrast Agents Are Not Created Equal
Epix Finally Sells Vasovist and Flips Debt, But Will It Escape Bankruptcy?
Epix Seeks New Vasovist Partner After Bayer Backs Out
Epix Seeks New Vasovist Partner After Bayer Backs Out
FDA Warns Against Gadolinium Use In MRIs For Kidney Failure Patients

Topics

Advertisement
UsernamePublicRestriction

Register

PS068707

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel